IN 201
Alternative Names: dPlus; IQ 201Latest Information Update: 10 Aug 2004
At a glance
- Originator Immune Network
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 26 Jul 2004 No development reported - Phase-I for Alzheimer's disease in Canada (unspecified route)
- 02 May 2001 Phase-I clinical trials for Alzheimer's disease in Canada (Unknown route)
- 12 Jan 2001 Preclinical development for Alzheimer's disease in Canada (Unknown route)